Drugs / NVG-111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04763083 | May 2021 → Dec 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +2 | NovalGen Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2023-12-10 | NovalGen Ltd. | Results NovalGen presents NVG-111 clinical data in hematological malignancies in an oral session and preclinical data for next-generation AR T cell engager NVG-222 at the 65th American Society of Hematology Annual Meeting novalgen.com ↗
The study showcased positive responses in 58% of evaluable patients with relapsed refractory chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) across both combination and monotherapy regimens, durable to 24 months. |
| 2023-11-02 | NovalGen Ltd. | Results NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting novalgen.com ↗
Our comprehensive findings reveal highly favorable safety and efficacy outcomes among patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), with patients demonstrating encouraging activity in both monotherapy and combination therapy groups. |
| 2022-11-03 | NovalGen Ltd. | Results NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting novalgen.com ↗ |
| 2022-05-26 | NovalGen Ltd. | Results NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting novalgen.com ↗
Early signs of efficacy and evidence of response was observed in all patients from Cohort 2 onwards. |
| 2021-05-20 | NovalGen Ltd. | Results NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma novalgen.com ↗
The data demonstrates NVG-111 eliciting potent killing at low concentrations of the drug. |
| 2021-04-07 | NovalGen Ltd. | Regulatory NovalGen receives CTA approval to start a Phase 1/2 first in human study to evaluate the safety, pharmacokinetics and efficacy of NVG-111 in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma novalgen.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVG-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04763083 ↗ |
| Action | Deplete | “resulting in targeted killing of the cancer cells” NCT04763083 ↗ |
| Route | Intravenous | “NVG-111 by continuous intravenous infusion” NCT04763083 ↗ |
| Target | ROR1 | “one arm binding to ROR1 on cancer cells” NCT04763083 ↗ |